Melanoma Skin Cancer

+ -Text Size

What`s New in Skin Cancer - Melanoma Research? TOPICS

What’s new in research and treatment of melanoma skin cancer?

Research into the causes, prevention, and treatment of melanoma is being done in medical centers throughout the world.

Causes, prevention, and early detection

Sunlight and ultraviolet (UV) radiation

Recent studies suggest there may be 2 general ways that UV exposure is linked to melanoma, but there is likely some overlap.

The first link is to sun exposure as a child and teenager. People with melanoma often have an early history of sunburns or other intense sun exposures, although not everyone does. This early sun exposure may cause changes in the DNA of skin cells (melanocytes) that starts them on a path to becoming melanoma cells many years later. Some doctors think this might help explain why melanomas often occur on the legs and trunk, areas that generally aren’t exposed to the sun as much in adulthood.

The second link is to melanomas that occur on the arms, neck, and face. These areas are chronically exposed to sun, particularly in men.

Tanning booths may encourage either kind of melanoma to develop.

Researchers are looking to see if melanomas that develop from these types of UV exposure have different gene changes that might require them to be treated differently.

Public education

Most skin cancers can be prevented. The best way to reduce the number of skin cancers and the pain and loss of life from this disease is to educate the public, especially parents, about skin cancer risk factors and warning signs. It’s important for health care professionals and skin cancer survivors to remind everyone about the dangers of too much UV exposure (both from the sun and from man-made sources such as tanning beds) and about how easy it can be to protect your skin against too much UV radiation.

Melanoma can often be detected early, when it is most likely to be cured. Monthly skin self-exams and awareness of the warning signs of melanomas may be helpful in finding most melanomas when they are at an early, curable stage.

The American Academy of Dermatology (AAD) sponsors annual free skin cancer screenings throughout the country. Many local American Cancer Society offices work closely with the AAD to provide volunteers for registration, coordination, and education efforts related to these free screenings. Look for information in your area about these screenings or call the American Academy of Dermatology for more information. Their phone number and website are listed in the “Additional resources” section.

Along with recommending staying in the shade, the American Cancer Society uses a slogan popularized in Australia as part of its skin cancer prevention message in the United States. “Slip! Slop! Slap!®… and Wrap” is a catchy way to remember when going outdoors to slip on a shirt, slop on sunscreen, slap on a hat, and wrap on sunglasses to protect your eyes and the sensitive skin around them.

Melanoma genetic research

Scientists have made a great deal of progress during the past few years in understanding how UV light damages DNA inside skin cells and how these changes can cause normal skin cells to become cancerous.

Some people, though, inherit mutated (damaged) genes from their parents. For example, changes in the CDKN2A (p16) gene cause some melanomas to run in certain families. People who have a strong family history of melanoma should speak with a cancer genetic counselor or a doctor experienced in cancer genetics to discuss the possible benefits, limits, and downsides of testing for changes in this gene.

Lab tests to help determine prognosis

Most melanomas found at an early stage can be cured with surgery. But a small portion of these cancers eventually spread to other parts of the body, where they can be hard to treat.

Recent research has shown that certain gene expression patterns in melanoma cells can help show if stage I or II melanomas are likely to spread. A lab test based on this research, known as DecisionDx-Melanoma, is now available. The test divides melanomas into 2 groups based on their gene patterns:

  • Class 1 tumors have a low risk of spreading.
  • Class 2 tumors have a higher risk of spreading.

This test might help tell if someone with early stage melanoma should get additional treatment or if they need to be followed more closely after treatment to look for signs of recurrence.


While early-stage melanomas can often be cured with surgery, more advanced melanomas can be much harder to treat. But in recent years, newer types of immunotherapy and targeted therapies have shown a great deal of promise and have changed the treatment of this disease.


This type of treatment helps the body’s immune system attack melanoma cells more effectively. Some forms of immune therapy are already used to treat some melanomas (see “Immunotherapy for melanoma skin cancer”).

Drugs that block CTLA-4: Ipilimumab targets CTLA-4, a protein that normally suppresses the T-cell immune response, which might help melanoma cells survive. Ipilimumab has been shown to help some people with advanced melanomas live longer, and is already being used to treat some people with advanced melanoma.

A recent early study found that combining ipilimumab with another immunotherapy drug known as GM-CSF helped patients with advanced melanoma live longer than those who got just ipilimumab alone. The people who got the combination also seemed to have fewer serious side effects. Further clinical trials are testing ipilimumab combined with this or other drugs.

Drugs that block PD-1 or PD-L1: Melanoma cells also use other natural pathways in the body to help avoid being detected and destroyed by the immune system. For example, they often have a protein called PD-L1 on their surface that helps them evade the immune system.

New drugs that block the PD-L1 protein, or the corresponding PD-1 protein on immune cells called T cells, can help the immune system recognize the melanoma cells and attack them. Two drugs that block PD-1, pembrolizumab (Keytruda) and nivolumab (Opdivo), are now approved to treat advanced melanoma. In early studies, these drugs have shrunk tumors in about one quarter to one-third of people with melanoma, which is better than most results seen with ipilimumab. These drugs appear to have fewer serious side effects as well, and many of the tumor responses have been long-lasting so far. Larger studies of these new drugs are now being done, including some that use one of these drugs with ipilimumab to see if the combination might work even better.

Melanoma vaccines: Vaccines directed at melanoma are being studied in clinical trials. These are experimental therapies that have not yet been proven to be helpful.

These vaccines are, in some ways, like the vaccines used to prevent diseases such as polio, measles, and mumps that are caused by viruses. Such vaccines usually contain weakened viruses or parts of a virus that cannot cause the disease. The vaccine stimulates the body’s immune system to destroy the more harmful type of virus.

In the same way, killed melanoma cells or parts of cells (antigens) can be used as a vaccine to try to stimulate the body’s immune system to destroy other melanoma cells in the body. Usually, the cells or antigens are mixed with other substances that help boost the body’s immune system as a whole. But unlike vaccines that are meant to prevent infections, these vaccines are meant to treat an existing disease.

Making an effective vaccine against melanoma has proven to be harder than making a vaccine to fight a virus. The results of studies using vaccines to treat melanoma have been mixed so far, but many newer vaccines are now being studied and may hold more promise.

Other immunotherapies: Other forms of immunotherapy are also being studied. Some early studies have shown that treating patients with high doses of chemotherapy and radiation therapy and then giving them tumor-infiltrating lymphocytes (TILs), which are immune system cells found in tumors, can shrink melanoma tumors and possibly prolong life as well. Newer studies are looking at changing certain genes in the TILs before they are given to see if this can make them more effective at fighting the cancer. This approach has looked promising in early studies, but it is complex and is only being tested in a few centers.

Many studies are now looking to combine different types of immunotherapy, which may be more effective than any single treatment for advanced melanoma.

Targeted drugs

As doctors have discovered some of the gene changes in melanoma cells, they have developed drugs that attack these changes. These targeted drugs work differently from standard chemotherapy drugs. They may work in some cases when chemotherapy doesn’t. They may also have less severe side effects.

Drugs that target cells with changes in the BRAF gene: As noted in the section “Targeted therapy for melanoma skin cancer,” about half of all melanomas have changes in the BRAF gene, which helps the cells grow. Drugs that target the BRAF protein, such as vemurafenib (Zelboraf) and dabrafenib (Tafinlar), as well as drugs that target the related MEK proteins, such as trametinib (Mekinist) and cobimetinib (Cotellic), have been shown to shrink many of these tumors. These drugs are now often used in melanomas that test positive for the BRAF gene change. Other, similar drugs are now being studied as well.

One of the drawbacks of these drugs is that they seem to work for only a limited time before the cancer starts growing again. A new approach is to combine a BRAF inhibitor with a MEK inhibitor. Study results have been promising, showing that combining the drugs results in longer response times and that some side effects (such as the development of other skin cancers) might actually be less common with the combination.

Drugs that target cells with changes in the C-KIT gene: A small number of melanomas have changes in the C-KIT gene. This is more likely in melanomas that start on the palms of the hands, soles of the feet, under the nails, or in certain other places.

Clinical trials are now testing drugs such as imatinib (Gleevec) and nilotinib (Tasigna), which are known to target cells with changes in C-KIT.

Drugs that target other gene or protein changes: Several drugs that target other abnormal genes or proteins, such as sorafenib (Nexavar), bevacizumab (Avastin), pazopanib (Votrient), and everolimus (Afinitor), are now being studied in clinical trials as well.

Researchers are also looking at combining some of these targeted drugs with other types of treatments, such as chemotherapy or immunotherapy.

Last Medical Review: 03/19/2015
Last Revised: 11/10/2015